Concept to commercialisation: a behind the scenes look at translating medical research into patient-ready treatments & vaccines
Adelaide, South Australia
Concept to commercialisation: a behind the scenes look at translating medical research into patient-ready treatments & vaccines
DESCRIPTION
What a relevant topic in todays climante of uncertainty a panel discussion on the concept to commercialisation: a behind the scenes look at translating medical research into patient-ready treatments & vaccines with a panel comprising of Dr Stephen Rodda, Dr Grubor-Bauk and Professor Toby Coates
Dr Stephen Rodda (Chair) is the Executive Director: Innovation and Commercial Partnerships at The University of Adelaide. Dr Rodda has 16+ years of experience in the areas of scientific research, research management, technology commercialisation, investment management and corporate governance. He is passionate about the successful translation of research into outcomes that deliver social and economic benefit to our communities. Educated at the University of Adelaide, he gained a first-class honours degree, a PhD in Biochemistry and was awarded the University Medal. Subsequently he was awarded the prestigious CJ Martin and Arthritis Foundation fellowships for post-doctoral training at Harvard University. Dr Rodda holds an MBA, is a Fellow of the Australian Institute of Company Directors and has undertaken the Advanced Management Program (AMP) at the Harvard Business School. He is also Chair of Cost-Bry Pty Ltd (trading as BiomeBank).
Dr Grubor-Bauk is the Head of Viral Immunology at the Adelaide Medical School. She trained as a virologist, immunologist, and vaccine scientist and after postdoctoral training and a period in Biotech, she now leads a collaborative research program with basic science and translational components. Viral Immunology group is also involved in a number of different commercial research partnerships, with an aim to develop solutions with clinical application.
The lab is focused on the development of promising Zika virus, hepatitis C and HIV vaccines, and recently SARS-CoV-2, employing various cutting edge techniques in viral vaccine design and development, supported by broad experience in animal models, including infection models, in vitro and in vivo vaccine validation assays (antigen presentation, B, T cell assays, in vivo epitope mapping, fluorescent target array assay), multi-parametric flow cytometry, antibody and cytokine assays (ELISA, neutralisation assays, intracellular cytokine staining).
Professor Toby Coates is a Renal Transplant Nephrologist at the Royal Adelaide Hospital (RAH), whose work in the area of kidney and pancreatic islet cell transplantation has saved the lives of countless diabetes and kidney disease patients across South Australia. One of the highlights of his career is successfully performing the first islet cell transplant surgery in SA in 2010 as a cure for type 1 diabetes, with his research heavily supported by The Hospital Research Foundation Group. Prof Coates also leads the School of Medicine in the Central Northern Adelaide Renal and Transplantation Service (CNARTS) at the RAH, focusing on the isolation and transplantation of healthy pancreatic islets as an innovative treatment and potential cure for type 1 diabetes. Prof Coates is committed to improving the lives of those living with kidney disease and diabetes.